As resistance of these tissues to insulin leads to reduced glucose disposal, hyperglycemia, and ultimately diabetes-associated cardiovascular disease, the beneficial effects of pharmacological PPARγ activators are attributed to their insulin-sensitising actions on glucose-utilising tissues, which when summed together comprise a systemic anti-hyperglycaemic impact [84]. The gene discussed is INS; the disease is diabetes mellitus.